SLNO Key Statistics, Chart & Performance
The current stock price of SLNO is 42.48 USD. In the past month the price decreased by -13.75%. In the past year, price decreased by -9.39%.
SLNO Technical Analysis
SLNO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLNO. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability.
SLNO Financial Highlights
Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 44.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.08% | ||
| ROE | -15.85% | ||
| Debt/Equity | 0.1 |
SLNO Forecast & Estimates
19 analysts have analysed SLNO and the average price target is 112.75 USD. This implies a price increase of 165.42% is expected in the next year compared to the current price of 42.48.
SLNO Ownership
SLNO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About SLNO
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 152 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
SOLENO THERAPEUTICS INC
100 Marine Parkway, Suite 400
Redwood City CALIFORNIA 94065 US
CEO: Anish Bhatnagar
Employees: 152
Phone: 16502138444
SOLENO THERAPEUTICS INC / SLNO FAQ
What does SOLENO THERAPEUTICS INC do?
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 152 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Can you provide the latest stock price for SOLENO THERAPEUTICS INC?
The current stock price of SLNO is 42.48 USD. The price increased by 1.26% in the last trading session.
Does SOLENO THERAPEUTICS INC pay dividends?
SLNO does not pay a dividend.
What is the ChartMill rating of SOLENO THERAPEUTICS INC stock?
SLNO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is SOLENO THERAPEUTICS INC (SLNO) stock traded?
SLNO stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for SOLENO THERAPEUTICS INC?
SOLENO THERAPEUTICS INC (SLNO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for SOLENO THERAPEUTICS INC?
SOLENO THERAPEUTICS INC (SLNO) currently has 152 employees.